Genmab A/S (NASDAQ:GMAB) Rating Reiterated by HC Wainwright

Genmab A/S (NASDAQ:GMAB - Get Free Report)'s stock had its "buy" rating reaffirmed by analysts at HC Wainwright in a research report issued on Tuesday, Benzinga reports. They currently have a $50.00 target price on the stock. HC Wainwright's price objective would suggest a potential upside of 80.57% from the stock's current price.

GMAB has been the subject of several other reports. Morgan Stanley reaffirmed an "underweight" rating on shares of Genmab A/S in a report on Tuesday, March 26th. Truist Financial reaffirmed a "buy" rating and issued a $50.00 price target on shares of Genmab A/S in a research report on Tuesday, March 26th. BMO Capital Markets raised Genmab A/S from a "market perform" rating to an "outperform" rating and boosted their price objective for the stock from $46.00 to $48.00 in a research report on Friday, February 23rd. Finally, Citigroup lowered Genmab A/S from a "neutral" rating to a "sell" rating in a report on Monday, January 22nd. Three equities research analysts have rated the stock with a sell rating, two have given a hold rating and eight have given a buy rating to the company. According to data from MarketBeat.com, Genmab A/S presently has an average rating of "Hold" and an average price target of $48.50.

Genmab A/S Stock Down 3.1 %

Shares of NASDAQ:GMAB traded down $0.88 on Tuesday, reaching $27.69. The company had a trading volume of 933,125 shares, compared to its average volume of 586,815. The stock has a market capitalization of $18.31 billion, a P/E ratio of 28.84, a P/E/G ratio of 2.02 and a beta of 0.98. The stock has a 50-day moving average price of $29.41 and a 200 day moving average price of $29.94. Genmab A/S has a twelve month low of $26.32 and a twelve month high of $42.72.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last issued its quarterly earnings data on Wednesday, February 14th. The company reported $0.36 earnings per share for the quarter, beating analysts' consensus estimates of $0.34 by $0.02. The business had revenue of $675.29 million for the quarter, compared to the consensus estimate of $678.14 million. Genmab A/S had a return on equity of 18.06% and a net margin of 26.50%. On average, sell-side analysts predict that Genmab A/S will post 1.06 earnings per share for the current fiscal year.

Institutional Trading of Genmab A/S

Institutional investors and hedge funds have recently modified their holdings of the company. HBK Sorce Advisory LLC boosted its stake in Genmab A/S by 4.8% during the third quarter. HBK Sorce Advisory LLC now owns 9,139 shares of the company's stock worth $322,000 after buying an additional 419 shares in the last quarter. China Universal Asset Management Co. Ltd. boosted its position in shares of Genmab A/S by 86.3% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 1,075 shares of the company's stock valued at $38,000 after acquiring an additional 498 shares in the last quarter. Park Place Capital Corp increased its stake in Genmab A/S by 12.3% in the fourth quarter. Park Place Capital Corp now owns 4,891 shares of the company's stock valued at $156,000 after acquiring an additional 535 shares during the period. Grandfield & Dodd LLC increased its stake in Genmab A/S by 2.3% in the fourth quarter. Grandfield & Dodd LLC now owns 25,558 shares of the company's stock valued at $814,000 after acquiring an additional 565 shares during the period. Finally, Pinnacle Bancorp Inc. raised its position in Genmab A/S by 315.8% in the fourth quarter. Pinnacle Bancorp Inc. now owns 840 shares of the company's stock worth $27,000 after purchasing an additional 638 shares in the last quarter. 7.07% of the stock is currently owned by institutional investors.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.